Lantern Pharma is trading 5.51% up at $2.01, with no clear catalyst identified.
- No September 8, 2026 company-specific announcement, filing, analyst action, or other clear catalyst was identified in available coverage.
- Recent clinical progress and second-quarter results predate the move and do not establish direct causation.
- The broader market is lower, while limited activity and no reliable live-volume confirmation leave the gain unexplained.